Sodium restriction potentiates the renoprotective effects of combined Vitamin D receptor activation and angiotensin-converting enzyme inhibition in established proteinuric nephropathy

Nephrology Dialysis Transplantation

Volumn 32, Issue 8, 2017, Pages 1293-1301

  Mirkovic, Katarina ^a   Frenay, Anne Roos S ^a   Van Den Born, Jacob ^a   Van Goor, Harry ^a   Navis, Gerjan ^a   De Borst, Martin H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

chronic kidney disease; proteinuria; renin angiotensin aldosterone system; sodium; Vitamin D

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; DOXORUBICIN; LISINOPRIL; MONOCYTE CHEMOTACTIC PROTEIN 1; PARICALCITOL; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR; VITAMIN D RECEPTOR; BONE DENSITY CONSERVATION AGENT; CALCITRIOL RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERGOCALCIFEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME INHIBITION; FOCAL GLOMERULOSCLEROSIS; HIGH SODIUM INTAKE; KIDNEY FUNCTION; KIDNEY INTERSTITIUM; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; RENAL PROTECTION; SODIUM INTAKE; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; ADMINISTRATION AND DOSAGE; ANIMAL; BLOOD PRESSURE; CHEMISTRY; COMPLICATION; DRUG EFFECTS; KIDNEY; MEMBRANOUS GLOMERULONEPHRITIS; METABOLISM; PATHOLOGY; PHARMACOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT INTAKE; WISTAR RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; BONE DENSITY CONSERVATION AGENTS; DIET, SODIUM-RESTRICTED; ERGOCALCIFEROLS; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; KIDNEY; LISINOPRIL; MALE; PEPTIDYL-DIPEPTIDASE A; PROTEINURIA; RATS; RATS, WISTAR; RECEPTORS, CALCITRIOL; RENIN-ANGIOTENSIN SYSTEM; SODIUM CHLORIDE, DIETARY; SODIUM, DIETARY;

EID: 85026858799     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv304     Document Type: Article

References (27)

1. Jafar TH, Schmid CH, LandaMet al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann InternMed 2001; 135: 73-87
2. Vogt L, Waanders F, Boomsma F, et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19: 999-1007
3. Kwakernaak AJ, Krikken JA, Binnenmars SH, et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: A randomised clinical trial. Lancet Diabetes Endocrinol 2014; 2: 385-395
4. Vegter S, Perna A, PostmaMJ, et al. Sodiumintake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 2012; 23: 165-173
5. Heerspink HJ, Holtkamp FA, Parving HH, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 2012; 82: 330-337
6. Lambers Heerspink HJ, de BorstMH, Bakker SJ, et al. Improving the efficacy of RAAS blockade in patients with chronic kidney disease. Nat Rev Nephrol 2013; 9: 112-121
7. Mirkovic K, van den Born J, Navis G, et al. Vitamin D in chronic kidney disease: New potential for intervention. Curr Drug Targets 2011; 12: 42-53
8. de Borst MH, Hajhosseiny R, Tamez H, et al. Active vitamin D treatment for reduction of residual proteinuria: A systematic review. J Am Soc Nephrol 2013; 24: 1863-1871
9. de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet 2010; 376: 1543-1551
10. Kramer AB, Laverman GD, van Goor H, et al. Inter-individual differences in anti-proteinuric response to ACEi in established adriamycin nephrotic rats are predicted by pretreatment renal damage. J Pathol 2003; 201: 160-167
11. Wapstra FH, Van Goor H, Navis G, et al. Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Clin Sci (Lond) 1996; 90: 393-401
12. Watanabe N, Kamei S, Ohkubo A, et al. Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. Clin Chem 1986; 32: 1551-1554
13. Heeg JE, de Jong PE, van der Hem GK, et al. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36: 272-279
14. Fabris B, Jackson B, Johnston CI. Salt blocks the renal benefits of ramipril in diabetic hypertensive rats. Hypertension 1991; 17: 497-503
15. Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997; 51: 793-797.
16. Holtkamp FA, de Zeeuw D, Thomas MC, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-termrenal function. Kidney Int 2011; 80: 282-287
17. Humalda JK, Navis G. Dietary sodium restriction: A neglected therapeutic opportunity in chronic kidney disease. Curr Opin Nephrol Hypertens 2014; 23: 533-540
18. Kramer AB, Bos H, van Goor H, et al. Sodium intake modifies the negative prognostic value of renal damage prior to treatment with ACE inhibitors on proteinuria induced by adriamycin. Nephron Physiol 2006; 103: 43-52
19. Liu Y. Cellular andmolecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011; 7: 684-696
20. Doorenbos CR, van den Born J, Navis G, et al. Possible renoprotection by vitamin D in chronic renal disease: Beyond mineral metabolism. Nat Rev Nephrol 2009; 5: 691-700
21. Zhang Z, Zhang Y, Ning G, et al. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase. Proc Natl Acad Sci USA 2008; 105: 15896-15901
22. Zhang Y, Deb DK, Kong J, et al. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: Strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol 2009; 297: F791-F801
23. Deb DK, Sun T, Wong KE, et al. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int 2010; 77: 1000-1009
24. Slagman MC, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: Randomised controlled trial. BrMed J 2011; 343: D4366
25. Weir MR, Yadao AM, Purkayastha D, et al. Effects of high-and low-sodium diets on ambulatory blood pressure in patients with hypertension receiving aliskiren. J Cardiovasc Pharmacol Ther 2010; 15: 356-363
26. Laverman GD, Van Goor H, Henning RH, et al. Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes. Kidney Int 2003; 63: 64-71
27. Keyzer CA, de Jong MA, van Breda GF, et al. Vitamin D receptor activator and dietary sodium restriction to reduce residual urinary albumin excretion in chronic kidney disease (ViRTUE study): Rationale and study protocol. Nephrol Dial Transplant 2016; 31: 1081-1087